|
|
|
|
|
|
|
19/09/2007 |
|
|
Effect of miglustat on bone disease in adult Type 1 Gaucher Disease (GD1) |
|
|
|
|
 |
|
|
|
|
|
|
|
LONDON – 17 September 2007 – Actelion UK Ltd announces the publication of "Effect of miglustat on bone disease in adult type 1 Gaucher disease: a pooled analysis of three multinational open label studies" (Pastores et al.) in Clinical Therapeutics, vol 29, number 8, 2007.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
30/09/2007 |
|
|
One-Year results on the use of miglustat (Zavesca®) in Niemann-Pick type C disease |
|
|
|
|
 |
|
|
|
|
|
|
|
ALLSCHWIL, SWITZERLAND – 30 August 2007 – Actelion Ltd (SWX: ATLN) announced today the online publication in “The Lancet Neurology “ of the one-year results from a randomized controlled study evaluating safety and efficacy of miglustat (Zavesca®) in patients suffering from Niemann-Pick type C (NP-C) [1]. NP-C is an autosomal recessive genetic disease affecting children, juveniles and adults, characterized by progressive, severe and heterogeneous neurological manifestations, and reduced life expectancy [2]. Zavesca® is not currently licensed for the treatment of NP-C. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
06/06/07 |
|
|
Santé Communications Joins FD |
|
|
|
|
 |
|
|
|
|
|
|
|
Santé Communications Ltd is delighted to announce that, from today, it becomes part of the FD (Financial Dynamics) group. As most of you will know, we have been expanding our global offering for a number of years and the FD network will greatly enhance our ability to do this on behalf of our clients. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
17/04/07 |
|
|
EVERY CLICK COUNTS for Sport |
|
|
|
|
 |
|
|
|
|
|
|
|
17th April 2007, World Haemophilia Day – A new web resource for people with haemophilia, their carers and healthcare professionals was launched today with an innovative fund-raising campaign that aims to get more UK youngsters with haemophilia involved in sports. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
01/02/07 |
|
|
Medical Editor of Daily Telegraph to Join Santé |
|
|
|
|
 |
|
|
|
|
|
|
|
Santé Communications are delighted to announce that one of the UK’s most respected medical journalists is set to join the Agency.
National newspaper medical journalist, Celia Hall is leaving The Daily Telegraph for a new career with Santé Communications, a specialist healthcare communications consultancy, where she becomes Director of Media Strategy, a newly created post, as the agency seeks to expand its media offering.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
29/01/07 |
|
|
Baxter's Advate Receives Room Temperature Storage Approval |
|
|
|
|
 |
|
|
|
|
|
|
|
Compton, England, 29th January 2007 – Baxter Healthcare Ltd. today announced the approval of room temperature storage for Advate, the only factor VIII product processed without blood-based additives. The approval in the European Union allows for 2 months of room temperature storage within the approved shelf life of 24 months at 2° to 8°C. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
11/12/06 |
|
|
GLOBALHealthPR Extends Global Reach |
|
|
|
|
 |
|
|
|
|
|
|
|
11th December 2006: GLOBALHealthPR has announced the addition of three new members, LBS Co. Ltd (LBS) of Japan, MHC Communication (MHC) of France and Noesis Comunicazione (Noesis) of Italy.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
16/09/06 |
|
|
European mental health groups unite to issue call to action on metabolics in mental health |
|
|
|
|
 |
|
|
|
|
|
|
|
And leading clinicians name UNITE Survey a ‘wake up call to psychiatry’
PARIS, September 16th:
GAMIAN-Europe and EUFAMI today issued a call for action to address a growing crisis for people with mental illness – the relentless increase in CHD risk in this population. The statement followed presentation of the results of one of the largest ever global patient and carer surveys in psychiatry . It was echoed by demands for the clinical community to urgently address the physical health of their patients, by leading international clinicians who dubbed the results ‘staggering’.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
10/08/06 |
|
|
Advate’s safety profile confirmed |
|
|
|
|
 |
|
|
|
|
|
|
|
August 10th 2006 – The MHRA has announced the removal of Advate’s (Octocog Alfa Recombinant Coagulation Factor VIII) black triangle symbol, confirming its risk/benefit balance. The move marks the end of a period of detailed surveillance following the UK launch of Advate, the first and only haemophilia therapy without blood-based additives used for the prevention and control of bleeding episodes in people with haemophilia A. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
04/08/06 |
|
|
Introduction of new Advate convenience features |
|
|
|
|
 |
|
|
|
|
|
|
|
COMPTON, England, 4th August 2006 - Baxter Healthcare Ltd announced today the introduction of BAXJECT II, an innovative needle-less reconstitution device and an improved packaging design for its plasma-albumin-free haemophilia A therapy ADVATE. Introduction of these two new convenience features has just started and patients will begin to receive them in the coming weeks. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
18/05/06 |
|
|
Baxter and Jerini advance program to develop non-intravenous Hemophilia therapy |
|
|
|
|
 |
|
|
|
|
|
|
|
Deerfield, Ill. and Berlin, Germany, May 18, 2006 – Baxter AG and Jerini AG today announced progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analysis has identified several synthetic lead molecules with promising pharmacological properties.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
13/05/06 |
|
|
World Hypertension League calls for urgent action to get more hypertensive patients to Goal |
|
|
|
|
 |
|
|
|
|
|
|
|
Survey identifies important gaps in clinical practice that must be addressed to ensure more patients reach blood pressure goal
13th May 2006: Despite major advances in cardiovascular medicine, nearly 60% of hypertension patients in the UK have blood pressure that is not controlled to the recommended goal, leaving them at risk of serious cardiovascular disease1. Today the results of a global survey have been announced that uncover significant gaps between current and recommended hypertension management and give valuable insight into physician awareness of the importance of blood pressure goal achievement.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
23/02/06 |
|
|
Preotact® a new Medicine to help in the fight against Osteoporosis is on the Way |
|
|
|
|
 |
|
|
|
|
|
|
|
EU committee recommends that the Commission give EU marketing authorisation for a promising new osteoporosis drug from Nycomed. Preotact® strengthens and rebuilds bones enabling osteoporosis suffers a better chance of avoiding debilitating bone fractures.
Roskilde, 23 February 2006; Today, the treatment of osteoporosis took an important step forward when The European Committee for Medicinal Products for Human Use, CHMP, recommended the Commission to give Nycomed an EU marketing authorization for a promising new drug against “the silent disease”, osteoporosis.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
21/02/06 |
|
|
Santé Communications helping to Break the Sound Barrier |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 21st February 2006 – RNID, the largest charity for the UK’s nine million deaf and hard of hearing people, has appointed healthcare specialists Santé Communications to roll-out the regional arm of its high profile Breaking the Sound Barrier campaign. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
19/01/06 |
|
|
ABPI Appoints Agency to Work on New Code of Practice Awareness Campaign |
|
|
|
|
 |
|
|
|
|
|
|
|
The Association of the British Pharmaceutical Industry (ABPI) today announced plans to launch a major awareness campaign for the new Code of Practice. The ABPI has appointed Santé Communications, the specialist healthcare consultancy, to work on the campaign. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
01/11/05 |
|
|
Fresh Face at Santé |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 01 November 2005 – Santé Communications today announced the appointment of their new Graduate Trainee, Jennifer Marsden. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
02/08/05 |
|
|
Santé Climbs New Heights |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 2nd August 2005 – Santé Communications, the healthcare communications consultancy, today toasted the success of their colleague Tracy Highton’s daring fundraising efforts. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
12/07/05 |
|
|
Santé Communications Wins Major New Business Account |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 12th July 2005 – Santé Communications today announced a major new business win with Baxter Healthcare UK. Santé will provide a communications programme for the BioScience division of what is one of Europe’s largest healthcare companies employing over 1100 people in the UK alone. The Bioscience division encompasses a range of state-of-the-art products from vaccines and surgical sealants to therapies for clotting disorders and has a firm commitment to ensuring patient safety. Santé will be implementing a multifaceted programme for the division with a remit that covers NHS policy, corporate awareness and brand support. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
07/03/05 |
|
|
SMC Accepts Angiox™ use in Scotland |
|
|
|
|
 |
|
|
|
|
|
|
|
7th March, 2005, Glasgow - Angiox™ (bivalirudin), a short-acting thrombin-specific anticoagulant, is now approved for restricted use in NHS Scotland in patients undergoing PCI procedures such as angioplasty, balloon angioplasty and percutaneous transluminal coronary angioplasty (PCTA) with stenting. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
05/11/04 |
|
|
Ireland leading the way in Life Science |
|
|
|
|
 |
|
|
|
|
|
|
|
5th November 2004, London:- 200 leading scientists and entrepreneurs are meeting today in London to assess investment and growth in the Irish life science industry, at an Irish Government backed conference. To coincide with the meeting, the UK’s first all Irish scientific network, TechLink UK – Ireland will also be launched |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
29/09/04 |
|
|
New Graduates join Santé |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 29th September 2004: – Santé Communications today announced the appointment of two new Graduate Trainees, Helen Clark and Joe Delahunty. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
17Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
10/09/04 |
|
|
Santé Announces Exciting New Business Win |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 10th September 2004 - Santé Communications today announced a new business win with Nycomed UK Ltd.
Santé will lead a national awareness programme for the launch of Nycomed’s exciting new clot preventer (anticoagulant), AngioxTM.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
22Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
02/09/04 |
|
|
Santé to promote launch of UK-Ireland biotech network |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 02 September 2004: Santé Communications today announces its appointment as Secretariat for the launch of the first UK network for biotechnology and science in Ireland. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
22Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
10/06/04 |
|
|
Moves at Santé |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 10th June 2004 – Santé Communications today announced three promotions. Deborah Corcoran moves up to Account Manager, whilst Ben Yellowlees and Jennifer Mitchell have been made Junior Account Executives. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
37Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
06/05/04 |
|
|
Launch of first Pan-European Parkinson’s Nurse Journal |
|
|
|
|
 |
|
|
|
|
|
|
|
Lisbon, Portugal, 6th May 2004: The first ever Pan-European Journal for Parkinson’s Disease (PD) Nurse Specialists is being launched today. The EPNN (European Parkinson’s Nurse Network) Journal will bring nurses across Europe and other parts of the world closer together to share best practice and improve the quality of care for people with Parkinson’s. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
253Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
21/04/04 |
|
|
Santé Announces Major New Business Win |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 21st April 2004 - Santé Communications began a successful Easter, in the form of a major new business win, with Actelion. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
88Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
28/01/04 |
|
|
FIRST ALPHA BLOCKER LICENSED IN ACUTE URINARY RETENTION |
|
|
|
|
 |
|
|
|
|
|
|
|
28 January 2004 : Once daily Xatral XL 10mg (alfuzosin) has become the first and only alpha blocker licensed in acute urinary retention (AUR) in men aged ≥ 65 years. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
90kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
23/01/04 |
|
|
SANTÉ ANNOUNCES MAJOR NEW BUSINESS WIN |
|
|
|
|
 |
|
|
|
|
|
|
|
23 January 2004: Santé Communications commenced 2004 with a major new business win, from the Danish Pharmaceutical Company, Ferring Pharmaceuticals. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
11/11/03 |
|
|
Boehringer Ingelheim and Genentech Announce Clinical Trial |
|
|
|
|
 |
|
|
|
|
|
|
|
Evaluating Metalyse Use Prior to Angioplasty for Treatment of Heart Attack
ORLANDO, Florida, November 11, 2003- Boehringer Ingelheim and Genentech, Inc. announced at the American Heart Association congress, that a trial to test the single-bolus thrombolytic Metalyse® (tenecteplase) in combination with percutaneous coronary intervention (PCI) as a potentially improved treatment regimen for acute myocardial infarction (AMI) has started enrolment. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
10/11/03 |
|
|
Spanish Agency joins GLOBALHealthPR |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 10 November 2003 – GLOBALHealthPR today announced that a Spanish independent communication company is to become an affiliate member of the global health partnership. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
29/10/03 |
|
|
New Graduates join Santé |
|
|
|
|
 |
|
|
|
|
|
|
|
London, 29 September 2003 – Santé Communications today announced the appointment of two new Graduate Trainees, Jennifer Mitchell and Ben Yellowlees. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
01/09/03 |
|
|
Watford and Three Rivers to get UK’s first Cardiac Car |
|
|
|
|
 |
|
|
|
|
|
|
|
Local Paramedics Pioneer Life-saving Scheme
Watford, 1 September 2003: A pioneering initiative to save heart attack victims is being launched today in the Watford and Three Rivers Primary Care Trust area. Paramedics trained in administering life-saving clot-busting drugs will patrol the area in a car dedicated to responding immediately to chest pain patients. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
11/06/03 |
|
|
TALKING BPH - A New Information Service For Patients |
|
|
|
|
 |
|
|
|
|
|
|
|
Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting older men, yet many men are reluctant to seek help or ask questions about it. Sanofi-Synthelabo has launched a new service for men with BPH that aims to provide accessible information. The new service, called Talking BPH, hopes to encourage men to take a more proactive role in managing their condition, an initiative consistent with the DOH directive to ‘empower’ patients. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
09/06/03 |
|
|
National Men’s Health Week June 9-15: Don’t Gamble with your Sexual Health! |
|
|
|
|
 |
|
|
|
|
|
|
|
Ladbrokes, Edgware Road, London, London, 9 June 2003: Jungle Queen Linda Barker and tennis ace Pat Cash today joined forces with the Men’s Health Forum and the Orchid Cancer Appeal to launch National Men’s Health Week (June 9-15 2003). The former Wimbledon favourite had a health make-over at Ladbrokes’ brand new flagship store as he and Linda served up a volley of support for making good health more accessible to men of all ages. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
05/05/03 |
|
|
'Look at me!' for Deaf Awareness Week |
|
|
|
|
 |
|
|
|
|
|
|
|
5-11th May sees the launch of the first Deaf Awareness Week by fifty deaf charities and organisations under the umbrella of the UK Council on Deafness. Deaf Awareness Week will involve a UK wide series of national and local events to raise awareness of the needs of the 8.7 million deaf or hard of hearing people in the UK, that is, 1 in 7 of the total population.1 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
17KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
29/04/03 |
|
|
Boots to introduce custom made hearing aids |
|
|
|
|
 |
|
|
|
|
|
|
|
London, Tuesday 29th April, 2003– Boots Hearingcare today announces the introduction of custom made in-the-ear hearing aids to its existing range of competitively priced hearing aids. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
22KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
18/03/03 |
|
|
Hearing Loss Increases But UK Patients Stay Silent |
|
|
|
|
 |
|
|
|
|
|
|
|
Although latest GP consultation figures1 show hearing loss consultations have increased by 30% over the last decade, other new research shows that many people with hearing loss could be suffering, quite literally, in silence as they take an average of six months to seek medical help2. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
20Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
28/01/03 |
|
|
Europe-wide Launch of First Treatment for Acute Ischaemic Stroke |
|
|
|
|
 |
|
|
|
|
|
|
|
(For publication outside the USA, Canada and Japan)
Ingelheim/Germany, 28 January 2003– Boehringer Ingelheim announced the European launch of Actilyse® as the first and only treatment for acute ischaemic stroke, during a press conference held today at the company’s headquarters in Ingelheim, Germany. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
122KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
22/10/02 |
|
|
GPs wake up to importance of sleep |
|
|
|
|
 |
|
|
|
|
|
|
|
22nd October 2002 - The first Primary Care Sleep Group, uniting GPs with an interest in sleep medicine, is announced today. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
281KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
15/10/02 |
|
|
Time to Challenge Inadequate Anaemia Treatment for Cancer Patients |
|
|
|
|
 |
|
|
|
|
|
|
|
October 2002 - A consensus statement launched at this week’s European Society for Medical Oncology Congress (ESMO) in Nice is set to challenge current UK treatment options for cancer-related anaemia. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
167KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
23/09/02 |
|
|
Boots Launches World's First Digital Disposable Hearing Aid - Hear More, See Less |
|
|
|
|
 |
|
|
|
|
|
|
|
Boots launched the world's first digital disposable hearing aid, Songbird DigitalTM, today. The revolutionary device, which is available in Boots Hearingcare centres nationwide, brings affordable digital hearing aid technology to the high street.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
180KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
03/09/02 |
|
|
Early Combination Of Carvedilol and ACE Inhibition Prevents Progression of Heart Failure |
|
|
|
|
 |
|
|
|
|
|
|
|
The clinical outcome of patients with mild chronic heart failure can be significantly improved by the early initiation of carvedilol (Dilatrend®), in combination with the ACE inhibitor enalapril, according to new study results presented at the European Society of Cardiology (ESC) Congress today. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
40KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
28/06/02 |
|
|
Switch to US-sourced plasma further strengthens safety track record of OCTAPLAS® |
|
|
|
|
 |
|
|
|
|
|
|
|
Coventry, UK, 28 June 2002 - Octapharma Limited has today announced it has written to haematologists and other specialists involved with the provision of blood products in the National Health Service (NHS) indicating a switch to United States (US) plasma in the manufacture of Octaplas supplied to the United Kingdom (UK).
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
128KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
25/06/02 |
|
|
Leading the way in Heart Failure MPs learn about impact of heart failure in the UK |
|
|
|
|
 |
|
|
|
|
|
|
|
Members of Parliament heard today that the vast majority (up to 90%) of patients with heart failure are not receiving beta-blocker therapy for their condition despite the guidance issued in the National Service Framework for Coronary Heart Disease two years ago. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
28KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
24/04/02 |
|
|
World’s Largest Independent Healthcare PR Organisation Launched Today |
|
|
|
|
 |
|
|
|
|
|
|
|
GLOBALHealthPR, the world’s largest independent organisation of specialist healthcare public relations consultants, was launched today. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
39KB |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
17/04/02 |
|
|
Santé Communications wins new business hat-trick |
|
|
|
|
 |
|
|
|
|
|
|
|
Santé Communications today announced winning three multi-agency pitches in six weeks worth over £400,000. |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
11Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
20/02/02 |
|
|
The HEART Solution |
|
|
|
|
 |
|
|
|
|
|
|
|
A new initiative which will help optimise the identification, diagnosis, treatment and after-care of patients with heart failure
Welwyn Garden City, UK, 20 February 2002 - Roche UK is pleased to announce the launch of the first integrated healthcare solution for tackling heart failure, The HEART Solution (HEart FAiluRe ManagemenT Solution). The HEART Solution gives health professionals such as nurses, GPs and hospital doctors an opportunity to work together to improve outcomes for patients and to help them meet the National Service Framework (NSF) targets for coronary heart disease.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
118Kb |
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
|
|
21/05/01 |
|
|
Life-saving clot-buster launched today |
|
|
|
|
 |
|
|
|
|
|
|
|
Today Boehringer Ingelheim launched tenecteplase (also known as TNK) for the treatment of heart attacks - the only currently licensed clot buster that can be given as a single injection, in under ten seconds.
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
|
 |
|
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |